BackAN2 Therapeutics Overview

AN2 Therapeutics Total Liabilities

Latest total liabilities for ANTX: $5.8M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$5.75M
17.59% YoYΔ $-1.23M vs prior year quarter

Peer trimmed avg / median

Loading

AN2 Therapeutics Total Liabilities History

Loading

AN2 Therapeutics vs. peers: Total Liabilities Comparison

Loading

AN2 Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AN2 Therapeutics (ANTX) FAQ

AN2 Therapeutics posts a total liabilities of $5.8M as of June 2026. That compares with $7M in the prior-year period — down 17.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, AN2 Therapeutics's total liabilities was $7M. The latest reading is $5.8M — a 17.6% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of AN2 Therapeutics's financial statement story. At $5.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ANTX's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AN2 Therapeutics's other metric pages and overview cover the third.